Pirtobrutinib: all 64 studies that test it
Page 1 of 1. Open to participants first (38), then studies with results posted, then the rest; newest registration first within each.
- Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLLNot yet recruitingNCT07831395Phase 2
- Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCLNot yet recruitingNCT07744737Phase 2
- Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCLNot yet recruitingNCT07744724Phase 2
- Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic LeukemiaRecruitingNCT07685717Phase 2
- Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted TherapyNot yet recruitingNCT07684950Phase 2
- Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).Not yet recruitingNCT07624799Phase 2
- Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell LymphomaNot yet recruitingNCT07622784Phase 2
- Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)Not yet recruitingNCT07548450Phase 2
- Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLRecruitingNCT07516093Phase 3
- Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibRecruitingNCT07428707Early Phase 1
- Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System LymphomaRecruitingNCT07416890Phase 2
- A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSLRecruitingNCT07350850Phase 2
- Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell LymphomaRecruitingNCT07285590Phase 2
- Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCLRecruitingNCT07255963Phase 2
- A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)RecruitingNCT07231952Phase 2
- Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID TrialRecruitingNCT07220187Phase 3
- A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingNCT07218341Phase 4
- PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell LymphomaNot yet recruitingNCT07207785Phase 2
- Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT07122609Phase 2
- Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).RecruitingNCT06967610Phase 2
- Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL TrialRecruitingNCT06948786Phase 2
- A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin LymphomaRecruitingNCT06876662Phase 4
- A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) PirtobrutinibRecruitingNCT06876649Phase 4
- Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With ZanubrutinibRecruitingNCT06812715Phase 2
- A Study of Pirtobrutinib in Participants With Immune ThrombocytopeniaRecruitingNCT06721013Phase 1/2
- A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingNCT06588478Phase 2
- Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCLRecruitingNCT06553872Phase 2
- Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKiRecruitingNCT06466122Phase 2
- Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)RecruitingNCT06390956Phase 2
- Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic LeukemiaRecruitingNCT06333262Phase 2
- Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) PatientsRecruitingNCT06263491Phase 2
- Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT06252675Phase 2
- Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationRecruitingNCT06043674Phase 2
- LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell MalignanciesRecruitingNCT05990465Phase 1
- A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.RecruitingNCT05833763Phase 2
- Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)RecruitingNCT05536349Phase 2
- Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) PatientsRecruitingNCT05529069Phase 2
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingNCT05254743Phase 3
- A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy ParticipantsCompletedNCT06258174Phase 1Results posted
- A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy ParticipantsCompletedNCT06215521Phase 1Results posted
- A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy ParticipantsCompletedNCT06215430Phase 1Results posted
- A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy ParticipantsCompletedNCT06194214Phase 1Results posted
- Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy ParticipantsCompletedNCT06190691Phase 1Results posted
- Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy ParticipantsCompletedNCT06190678Phase 1Results posted
- A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult ParticipantsCompletedNCT06181006Phase 1Results posted
- A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy ParticipantsCompletedNCT06180980Phase 1Results posted
- A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy ParticipantsCompletedNCT06180967Phase 1Results posted
- A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male ParticipantsCompletedNCT06180954Phase 1Results posted
- A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy ParticipantsCompletedNCT06165146Phase 1Results posted
- A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy ParticipantsCompletedNCT05176314Phase 1Results posted
- Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy ParticipantsCompletedNCT05134350Phase 1Results posted
- Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy ParticipantsCompletedNCT05134337Phase 1Results posted
- A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT05023980Phase 3Results posted
- A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)CompletedNCT04849416Phase 2Results posted
- Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT04666038Phase 3Results posted
- Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood CancersActive, not recruitingNCT07162181Phase 2
- A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaWithdrawnNCT06839872Phase 2
- GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT06522386Phase 2
- A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple SclerosisWithdrawnNCT06104683Phase 2
- Pirtobrutinib and Venetoclax in Waldenström MacroglobulinemiaActive, not recruitingNCT05734495Phase 2
- Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT05677919Phase 2
- Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With VenetoclaxTerminatedNCT05317936Phase 1/2
- A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT04965493Phase 3
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Active, not recruitingNCT04662255Phase 3